Eachy Biopharmaceuticals, Ltd is a ISO 13485 qualified company focused on developing and producing in vitro diagnostics for the prognosis of cardiovascular diseases, metabolic syndrome and the diagnosis of inflammatory diseases.

Founded in 2013, it has served a wide range of clientele with its proprietary technologies in biomarkers, human-derived antibodies and high throughput screening. Eachy currently owns 25 patents and three core technologies - chemiluminescence, time-resolved fluorescence immunoassay, and colloidal gold immunochromatography to manufacture high sensitivity and accuracy products.

In an effort to combat the recent COVID-19 pandemic, Eachy has developed 5 types of SARS-CoV-2 diagnostic testing kits which received the CE marking. Read more about the product here!